Floatz logo

15 assets in Malignant Urinary System Neoplasm

Therapeutic assets addressing Malignant Urinary System Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nivolumab
Malignant Urinary System Neoplasm
Spanish Oncology Genito-Urinary GroupP2B (60)
Tadalafil
Malignant Urinary System Neoplasm
Regina Elena Cancer InstituteP3B (60)
Atezolizumab
Malignant Urinary System Neoplasm
British Columbia Cancer AgencyP2B (58)
Ipilimumab
Malignant Urinary System Neoplasm
Dana-Farber Cancer InstituteP2B (58)
Riluzole
Malignant Urinary System Neoplasm
University of California, IrvineP2CCC (53)
Cyclophosphamide
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (46)
Dp Cd8 Til
Malignant Urinary System Neoplasm
AgonOx, Inc.P1CC (43)
Fludarabine
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (43)
Grt-C903
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (43)
Grt-R904
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (43)
Kras Tcr-Transduced Pbl
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (43)
pds01adc
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (41)